Novartis Financial Statements (NVS)
|
|
Report date
|
|
|
26.04.2022 |
31.12.2022 |
01.02.2023 |
15.05.2023 |
31.01.2024 |
|
30.09.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
52 877 |
51 828 |
51 828 |
51 828 |
46 660 |
|
49 289 |
Operating Income, bln rub |
|
|
26 948 |
9 197 |
9 197 |
9 197 |
9 769 |
|
13 766 |
EBITDA, bln rub |
? |
|
33 061 |
16 389 |
14 726 |
16 389 |
18 286 |
|
19 768 |
Net profit, bln rub |
? |
|
24 021 |
6 955 |
6 955 |
6 955 |
14 850 |
|
17 603 |
|
OCF, bln rub |
? |
|
15 071 |
14 236 |
14 236 |
14 236 |
14 458 |
|
15 973 |
CAPEX, bln rub |
? |
|
2 971 |
2 671 |
2 671 |
2 671 |
2 753 |
|
3 466 |
FCF, bln rub |
? |
|
12 100 |
11 565 |
11 565 |
11 565 |
11 705 |
|
12 507 |
Dividend payout, bln rub
|
|
|
7 368 |
7 506 |
7 506 |
7 506 |
7 255 |
|
7 624 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
Dividend payout ratio, %
|
|
|
30.7% |
107.9% |
107.9% |
107.9% |
48.9% |
|
43.3% |
|
OPEX, bln rub |
|
|
25 321 |
27 145 |
27 145 |
27 145 |
24 871 |
|
22 920 |
Cost of production, bln rub |
|
|
15 867 |
15 486 |
15 486 |
15 486 |
12 472 |
|
12 603 |
R&D, bln rub |
|
|
9 540 |
9 996 |
9 996 |
9 996 |
11 371 |
|
9 465 |
Interest expenses, bln rub |
|
|
811.0 |
837.0 |
837.0 |
837.0 |
855.0 |
|
948.0 |
|
Assets, bln rub |
|
|
131 795 |
117 453 |
117 453 |
117 453 |
99 945 |
|
103 524 |
Net Assets, bln rub |
? |
|
67 655 |
59 342 |
59 342 |
59 342 |
46 667 |
|
43 317 |
Debt, bln rub |
|
|
31 093 |
27 964 |
27 964 |
27 964 |
26 348 |
|
32 159 |
Cash, bln rub |
|
|
28 329 |
18 930 |
18 930 |
18 930 |
14 428 |
|
14 020 |
Net debt, bln rub |
|
|
2 764 |
9 034 |
9 034 |
9 034 |
11 920 |
|
18 139 |
|
Ordinary share price, rub |
|
|
82.8 |
90.7 |
85.9 |
85.9 |
101.0 |
|
84.0 |
Number of ordinary shares, mln |
|
|
2 243 |
2 181 |
2 181 |
2 181 |
2 077 |
|
2 012 |
|
Market cap, bln rub |
|
|
185 620 |
197 860 |
187 254 |
187 254 |
209 694 |
|
169 008 |
EV, bln rub |
? |
|
188 384 |
206 894 |
196 288 |
196 288 |
221 614 |
|
187 147 |
Book value, bln rub |
|
|
3 878 |
-1 603 |
-1 603 |
-1 603 |
-3 553 |
|
-9 515 |
|
EPS, rub |
? |
|
10.7 |
3.19 |
3.19 |
3.19 |
7.15 |
|
8.75 |
FCF/share, rub |
|
|
5.40 |
5.30 |
5.30 |
5.30 |
5.64 |
|
6.22 |
BV/share, rub |
|
|
1.73 |
-0.73 |
-0.73 |
-0.73 |
-1.71 |
|
-4.73 |
|
EBITDA margin, % |
? |
|
62.5% |
31.6% |
28.4% |
31.6% |
39.2% |
|
40.1% |
Net margin, % |
? |
|
45.4% |
13.4% |
13.4% |
13.4% |
31.8% |
|
35.7% |
FCF yield, % |
? |
|
6.52% |
5.85% |
6.18% |
6.18% |
5.58% |
|
7.40% |
ROE, % |
? |
|
35.5% |
11.7% |
11.7% |
11.7% |
31.8% |
|
40.6% |
ROA, % |
? |
|
18.2% |
5.92% |
5.92% |
5.92% |
14.9% |
|
17.0% |
|
P/E |
? |
|
7.73 |
28.4 |
26.9 |
26.9 |
14.1 |
|
9.60 |
P/FCF |
|
|
15.3 |
17.1 |
16.2 |
16.2 |
17.9 |
|
13.5 |
P/S |
? |
|
3.51 |
3.82 |
3.61 |
3.61 |
4.49 |
|
3.43 |
P/BV |
? |
|
47.9 |
-123.4 |
-116.8 |
-116.8 |
-59.0 |
|
-17.8 |
EV/EBITDA |
? |
|
5.70 |
12.6 |
13.3 |
12.0 |
12.1 |
|
9.47 |
Debt/EBITDA |
|
|
0.08 |
0.55 |
0.61 |
0.55 |
0.65 |
|
0.92 |
|
R&D/CAPEX, % |
|
|
321.1% |
374.2% |
374.2% |
374.2% |
413.0% |
|
273.1% |
|
CAPEX/Revenue, % |
|
|
5.62% |
5.15% |
5.15% |
5.15% |
5.90% |
|
7.03% |
|
Novartis shareholders |